These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 32369447)
21. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Cascone T; Leung CH; Weissferdt A; Pataer A; Carter BW; Godoy MCB; Feldman H; William WN; Xi Y; Basu S; Sun JJ; Yadav SS; Rojas Alvarez FR; Lee Y; Mishra AK; Chen L; Pradhan M; Guo H; Sinjab A; Zhou N; Negrao MV; Le X; Gay CM; Tsao AS; Byers LA; Altan M; Glisson BS; Fossella FV; Elamin YY; Blumenschein G; Zhang J; Skoulidis F; Wu J; Mehran RJ; Rice DC; Walsh GL; Hofstetter WL; Rajaram R; Antonoff MB; Fujimoto J; Solis LM; Parra ER; Haymaker C; Wistuba II; Swisher SG; Vaporciyan AA; Lin HY; Wang J; Gibbons DL; Jack Lee J; Ajami NJ; Wargo JA; Allison JP; Sharma P; Kadara H; Heymach JV; Sepesi B Nat Med; 2023 Mar; 29(3):593-604. PubMed ID: 36928818 [TBL] [Abstract][Full Text] [Related]
22. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. Paz-Ares LG; Ciuleanu TE; Pluzanski A; Lee JS; Gainor JF; Otterson GA; Audigier-Valette C; Ready N; Schenker M; Linardou H; Caro RB; Provencio M; Zurawski B; Lee KH; Kim SW; Caserta C; Ramalingam SS; Spigel DR; Brahmer JR; Reck M; O'Byrne KJ; Girard N; Popat S; Peters S; Memaj A; Nathan F; Aanur N; Borghaei H J Thorac Oncol; 2023 Jan; 18(1):79-92. PubMed ID: 36049658 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Tannir NM; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; Flaifel A; Pignon JC; Ficial M; Frontera OA; George S; Powles T; Donskov F; Harrison MR; Barthélémy P; Tykodi SS; Kocsis J; Ravaud A; Rodriguez-Cid JR; Pal SK; Murad AM; Ishii Y; Saggi SS; McHenry MB; Rini BI Clin Cancer Res; 2021 Jan; 27(1):78-86. PubMed ID: 32873572 [TBL] [Abstract][Full Text] [Related]
24. Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial. Tong TML; Burgmans MC; Speetjens FM; van Erkel AR; van der Meer RW; van Rijswijk CSP; Jonker-Bos MA; Roozen CFM; Sporrel-Blokland M; Lutjeboer J; van Persijn van Meerten EL; Martini CH; Zoethout RWM; Tijl FGJ; Blank CU; Kapiteijn E Cardiovasc Intervent Radiol; 2023 Mar; 46(3):350-359. PubMed ID: 36624292 [TBL] [Abstract][Full Text] [Related]
25. Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. Lei M; Siemers NO; Pandya D; Chang H; Sanchez T; Harbison C; Szabo PM; Janjigian Y; Ott PA; Sharma P; Bendell J; Evans TRJ; de Braud F; Chau I; Boyd Z Clin Cancer Res; 2021 Jul; 27(14):3926-3935. PubMed ID: 33782030 [TBL] [Abstract][Full Text] [Related]
26. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908. Dunkel IJ; Doz F; Foreman NK; Hargrave D; Lassaletta A; André N; Hansford JR; Hassall T; Eyrich M; Gururangan S; Bartels U; Gajjar A; Howell L; Warad D; Pacius M; Tam R; Wang Y; Zhu L; Cohen K Neuro Oncol; 2023 Aug; 25(8):1530-1545. PubMed ID: 36808285 [TBL] [Abstract][Full Text] [Related]
27. Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study. Oka Y; Matsumoto J; Takeda T; Iwata N; Niimura T; Ozaki AF; Bekku K; Hamano H; Araki M; Ishizawa K; Zamami Y; Ariyoshi N Int J Clin Pharm; 2024 Jun; 46(3):745-750. PubMed ID: 38632203 [TBL] [Abstract][Full Text] [Related]
28. Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. Winter J; Lenders MM; Gassenmaier M; Forschner A; Leiter U; Weide B; Purde MT; Flatz L; Cozzio A; Röcken M; Garbe C; Eigentler TK; Wagner NB Cancer Immunol Immunother; 2021 Apr; 70(4):1089-1099. PubMed ID: 33113003 [TBL] [Abstract][Full Text] [Related]
29. Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067. Baker T; Johnson H; Kotapati S; Moshyk A; Hamilton M; Kurt M; Paly VF Pharmacoecon Open; 2022 Sep; 6(5):697-710. PubMed ID: 36006606 [TBL] [Abstract][Full Text] [Related]
30. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. Armand P; Lesokhin A; Borrello I; Timmerman J; Gutierrez M; Zhu L; Popa McKiver M; Ansell SM Leukemia; 2021 Mar; 35(3):777-786. PubMed ID: 32601377 [TBL] [Abstract][Full Text] [Related]
31. Site-specific patterns of early response to nivolumab plus ipilimumab therapy in advanced renal cell carcinoma patients compared with tyrosine-kinase inhibitors. Kato R; Matsuura T; Maekawa S; Kato Y; Kanehira M; Takata R; Obara W Int Immunopharmacol; 2022 Dec; 113(Pt B):109443. PubMed ID: 36403521 [TBL] [Abstract][Full Text] [Related]
32. Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis. Bodensohn R; Werner S; Reis J; Pazos Escudero M; Kaempfel AL; Hadi I; Forbrig R; Manapov F; Corradini S; Belka C; Theurich S; Heinzerling L; Schlaak M; Niyazi M Clin Transl Radiat Oncol; 2023 Mar; 39():100573. PubMed ID: 36655118 [TBL] [Abstract][Full Text] [Related]
33. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. Xing P; Zhang F; Wang G; Xu Y; Li C; Wang S; Guo Y; Cai S; Wang Y; Li J J Immunother Cancer; 2019 Dec; 7(1):341. PubMed ID: 31801636 [TBL] [Abstract][Full Text] [Related]
34. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial. Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284 [TBL] [Abstract][Full Text] [Related]
35. Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study. Kido K; Hatakeyama S; Numakura K; Tanaka T; Oikawa M; Noro D; Hosogoe S; Narita S; Inoue T; Yoneyama T; Ito H; Nishimura S; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C Int J Clin Oncol; 2021 Jan; 26(1):154-162. PubMed ID: 33067647 [TBL] [Abstract][Full Text] [Related]
36. Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma. Tomita Y; Kimura G; Fukasawa S; Numakura K; Sugiyama Y; Yamana K; Naito S; Kaneko H; Tajima Y; Oya M Jpn J Clin Oncol; 2021 Nov; 51(11):1656-1664. PubMed ID: 34350454 [TBL] [Abstract][Full Text] [Related]
37. Factors associated with immunotherapy selection in patients with advanced melanoma. Joseph RW; Shillington AC; Macahilig C; Diede SJ; Dave V; Harshaw Q; Liu FX Immunotherapy; 2018 Nov; 10(16):1361-1369. PubMed ID: 30407098 [TBL] [Abstract][Full Text] [Related]
38. Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab. Blas L; Shiota M; Tsukahara S; Nagakawa S; Matsumoto T; Eto M Clin Genitourin Cancer; 2024 Feb; 22(1):e122-e127.e1. PubMed ID: 37813699 [TBL] [Abstract][Full Text] [Related]
39. Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer. Betts KA; Gao S; Ray S; Schoenfeld AJ Future Oncol; 2024 Apr; 20(13):851-862. PubMed ID: 38240151 [TBL] [Abstract][Full Text] [Related]
40. A Case of Metastatic Fumarate Hydratase-Deficient-like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab. Sekito T; Takamoto A; Kobayashi Y; Mitsui M; Watari S; Kubota R; Sadahira T; Iwata T; Nishimura S; Edamura K; Sako T; Araki M; Watanabe M; Watanabe T; Shibata R; Ennishi D; Nasu Y Acta Med Okayama; 2021 Jun; 75(3):397-402. PubMed ID: 34176946 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]